USFDA issues Form 483 for Glenmark Pharmaceuticals Ltd's Aurangabad facility

The U.S. FDA has issued Form 483 with one observation after an inspection at Glenmark Pharmaceuticals Limited's formulation manufacturing facility based out of Aurangabad, India between June 27, 2022 and July 1, 2022.

The company is committed to undertake all necessary steps required to address their observation at the earliest. The Company is committed to maintaining the highest quality manufacturing standards at all of its facilities across the globe.

Shares of Glenmark Pharmaceuticals Limited was last trading in BSE at Rs. 394.00 as compared to the previous close of Rs. 387.00. The total number of shares traded during the day was 29078 in over 1403 trades.

The stock hit an intraday high of Rs. 394.50 and intraday low of 382.05. The net turnover during the day was Rs. 11328414.00.

Source : Equity Bulls

Keywords

GlenmarkPharmaceuticals INE935A01035 Form483 OneObservation FormulationFacility Aurangabad